Scinopharm Taiwan (TPE:1789) Total Liabilities : NT$1,450 Mil (As of Mar. 2024)

View and export this data going back to 2011. Start your Free Trial

What is Scinopharm Taiwan Total Liabilities?

Scinopharm Taiwan's Total Liabilities for the quarter that ended in Mar. 2024 was NT$1,450 Mil.

Scinopharm Taiwan's quarterly Total Liabilities increased from Sep. 2023 (NT$1,324.71 Mil) to Dec. 2023 (NT$1,357.16 Mil) and increased from Dec. 2023 (NT$1,357.16 Mil) to Mar. 2024 (NT$1,449.87 Mil).

Scinopharm Taiwan's annual Total Liabilities increased from Dec. 2021 (NT$1,180.12 Mil) to Dec. 2022 (NT$1,461.12 Mil) but then declined from Dec. 2022 (NT$1,461.12 Mil) to Dec. 2023 (NT$1,357.16 Mil).

Scinopharm Taiwan Total Liabilities Historical Data

The historical data trend for Scinopharm Taiwan's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Scinopharm Taiwan Total Liabilities Chart

Scinopharm Taiwan Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

1,414.62

1,317.36

1,180.12

1,461.12

1,357.16

Scinopharm Taiwan Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Liabilities	Get a 7-Day Free Trial															1,513.25	1,712.86	1,324.71	1,357.16	1,449.87

Scinopharm Taiwan Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Scinopharm Taiwan's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	729.453	+	(570.231	+	2.958
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	54.514)
	=	1,357

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	11721.586	-	10364.43
	=	1,357

Scinopharm Taiwan's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	794.921	+	(627.699	+	2.8830000000001
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	24.369)
	=	1,450

Total Liabilities	=	Total Assets (Q: Mar. 2024 )	-	Total Equity (Q: Mar. 2024 )
	=	11974.808	-	10524.936
	=	1,450

Scinopharm Taiwan Total Liabilities Related Terms

Thank you for viewing the detailed overview of Scinopharm Taiwan's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Scinopharm Taiwan (TPE:1789) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Scinopharm Taiwan Ltd (TPE:1789) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 1, Nan-Ke 8th Road, Southern Taiwan Science Park, Shan-Hua, Tainan, TWN, 74144

Website

https://www.scinopharm.com

Scinopharm Taiwan Ltd is a specialty and generic drug manufacturing company. The company is primarily engaged in the manufacturing of medicines, chemicals, biological technology services, active pharmaceutical ingredients, albumin medicines, injections, and new small molecule drugs. Schinopharm also conducts consulting and technical services. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.

Scinopharm Taiwan (TPE:1789) Headlines

No Headlines